Prostate cancer progression after therapy of primary curative intent: a review of data from prostate-specific antigen era.
BACKGROUND
Radical prostatectomy and radiotherapy (RT), both radical therapies, are the standard treatments of curative intent for early prostate cancer. However, these therapies are not curative in all patients and, consequently, a substantial proportion of treated patients remain at risk of disease progression and/or cancer-related death.


METHODS
This article presents contemporary data on the incidence of prostate-specific antigen (PSA) and clinical disease progression after primary therapy of curative intent in relation to commonly assessed pretreatment or pathologic disease characteristics.


RESULTS
The data highlight the substantial risk of progression for certain patient groups, such as those with Gleason score 8-10, cT3 disease, lymph node metastases, and/or pretreatment PSA levels > 20 ng/mL.


CONCLUSIONS
Improved and/or additional treatment options are needed for these patient groups.
Soloway
Mark
M
Department of Urology, University of Miami School of Medicine, Miami, Florida 33136, USA. msoloway@miami.edu
Roach
Mack
M
D001918:Brachytherapy; D002986:Clinical Trials as Topic; D018450:Disease Progression; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000532:radiotherapy / Q000628:therapy*
D017430:Prostate-Specific Antigen